Adjunctive Group Psychotherapy for Moderate-to-Severe Atopic Dermatitis: A Pilot Feasibility Study Comparing Two Interventions
Atopic dermatitis is a chronic inflammatory skin disease characterized by eczematous skin lesions and pruritus. This partially randomized, three-arm pilot feasibility study was designed to evaluate two adjunctive group psychotherapy interventions in adults with moderate-to-severe atopic dermatitis receiving standard dermatological care.
Participants were assigned to one of three study arms: treatment as usual alone, treatment as usual plus atopic dermatitis-specific cognitive behavioural and schema mode group therapy, or treatment as usual plus stress management and resilience group therapy.
The psychotherapy interventions consisted of weekly group sessions during a 14-week intervention period. Assessments were scheduled at baseline, post-intervention at week 14, and six-month follow-up. Disease severity was assessed using the Eczema Area and Severity Index and SCORing Atopic Dermatitis.
Visão geral do estudo
Status
Condições
Descrição detalhada
This was a partially randomized, three-arm pilot feasibility study conducted in adults with moderate-to-severe atopic dermatitis. The study was designed to evaluate the feasibility of delivering two adjunctive group psychotherapy interventions in addition to standard dermatological care and to collect prespecified clinical, psychological, and feasibility-related outcomes.
Participants were recruited from an outpatient dermatology service. Eligible participants were adults with atopic dermatitis and baseline disease severity consistent with moderate-to-severe disease. All participants received treatment as usual, consisting of standard dermatological care according to clinical indication.
Participants were assigned to one of three study arms: treatment as usual alone; treatment as usual plus atopic dermatitis-specific cognitive behavioural and schema mode group therapy; or treatment as usual plus stress management and resilience group therapy. Participants allocated to the two psychotherapy arms were randomized between the two active group interventions. Assignment to the treatment-as-usual-only arm was non-randomized. The study was not blinded.
Both psychotherapy interventions consisted of 14 weekly group sessions. The atopic dermatitis-specific cognitive behavioural and schema mode group therapy intervention addressed disease-related psychological and behavioural processes, including itch-related coping, scratching behaviour, emotion regulation, stigma-related experiences, and schema mode work relevant to chronic skin disease. The stress management and resilience group therapy intervention addressed stress management, emotion regulation, interpersonal functioning, coping skills, and resilience.
Assessments were scheduled at baseline, post-intervention at week 14, and six-month follow-up. Disease severity was assessed using the Eczema Area and Severity Index and SCORing Atopic Dermatitis. Additional psychological and feasibility-related measures were collected as specified in the outcome measure section of the record.
The study was conducted with written informed consent from participants and approval from the relevant ethics committee.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Budapest, Hungria, 1083
- Department of Psychiatry and Psychotherapy, Semmelweis University
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Age 18 years or older
- Clinical diagnosis of atopic dermatitis
- Moderate-to-severe atopic dermatitis, defined as SCORing Atopic Dermatitis (SCORAD) score of 25 or higher
- Suitability for group psychotherapy confirmed through a secondary clinical interview with two psychotherapists
- Willingness to participate in the study and provide informed consent
Exclusion Criteria:
- Mild atopic dermatitis, defined as SCORAD score below 25
- Other chronic inflammatory or infectious skin disease
- Ongoing systemic immunosuppressive or biological treatment
- Psychotic disorder
- Drug dependence
- Pregnancy
- Not suitable for group psychotherapy based on the secondary clinical interview with two psychotherapists
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: TAU (standard dermatological treatment)
All groups received TAU as prescribed by a consultant dermatologist.
This included emollients, topical corticosteroids or calcineurin inhibitors, and antihistamines in line with European AD treatment guidelines.
|
All groups received TAU as prescribed by a consultant dermatologist.
This included emollients, topical corticosteroids or calcineurin inhibitors, and antihistamines in line with European AD treatment guidelines.
|
|
Experimental: TAU + Atopic Dermatitis-specific Cognitive Behavioural and Schema Mode Group Therapy
The ADCBST consisted of 14 weekly, 2.5-hour group sessions.
Therapy content was based on a structured manual combining schema mode therapy with atopic dermatitis-specific cognitive-behavioural strategies.
Sessions included psychoeducation, imagery rescripting, cognitive restructuring, behavioural experiments, and role-play exercises.
Therapy was delivered by two trained psychotherapists.
|
All groups received TAU as prescribed by a consultant dermatologist.
This included emollients, topical corticosteroids or calcineurin inhibitors, and antihistamines in line with European AD treatment guidelines.
The ADCBST consisted of 14 weekly, 2.5-hour group sessions.
Therapy content was based on a structured manual combining schema mode therapy with atopic dermatitis-specific cognitive-behavioural strategies.
Sessions included psychoeducation, imagery rescripting, cognitive restructuring, behavioural experiments, and role-play exercises.
Therapy was delivered by two trained psychotherapists.
|
|
Comparador Ativo: Stress Management and Resilience Group Therapy (SRCST)
The SRCST consisted of 14 weekly, 2.5-hour group sessions.
The SRCST intervention followed the Hungarian-adapted Williams LifeSkills protocol.
Sessions addressed emotion-focused and problem-focused coping, communication, empathy, and resilience.
Delivery was based on Carl Rogers' unconditional acceptance framework and Lewin's T-group method.
The 14 weekly sessions were led by a consultant psychologist and a psychology assistant.
|
All groups received TAU as prescribed by a consultant dermatologist.
This included emollients, topical corticosteroids or calcineurin inhibitors, and antihistamines in line with European AD treatment guidelines.
The SRCST consisted of 14 weekly, 2.5-hour group sessions.
The SRCST intervention followed the Hungarian-adapted Williams LifeSkills protocol.
Sessions addressed emotion-focused and problem-focused coping, communication, empathy, and resilience.
Delivery was based on Carl Rogers' unconditional acceptance framework and Lewin's T-group method.
The 14 weekly sessions were led by a consultant psychologist and a psychology assistant.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 14
Prazo: Baseline and week 14
|
The Eczema Area and Severity Index (EASI) is a clinician-rated measure of objective atopic dermatitis severity.
It evaluates erythema, excoriation, edema/papulation, and lichenification across four anatomical regions: head and neck, trunk, upper extremities, and lower extremities.
Total EASI scores range from 0 to 72, with higher scores indicating greater disease severity.
The outcome measure is the change in total EASI score from baseline to post-intervention assessment at week 14.
A negative change indicates improvement.
|
Baseline and week 14
|
|
Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 14
Prazo: Baseline and week 14
|
The SCORing Atopic Dermatitis (SCORAD) index is a clinician-rated and patient-informed measure of atopic dermatitis severity.
It includes assessment of disease extent, intensity of skin signs, and subjective symptoms including itching and sleep disturbance.
Total SCORAD scores range from 0 to 103, with higher scores indicating greater disease severity.
The outcome measure is the change in total SCORAD score from baseline to post-intervention assessment at week 14.
A negative change indicates improvement.
|
Baseline and week 14
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change From Baseline in Eczema Area and Severity Index (EASI) Score at Six-Month Follow-Up
Prazo: Baseline and six-month follow-up
|
The Eczema Area and Severity Index (EASI) is a clinician-rated measure of objective atopic dermatitis severity.
Total EASI scores range from 0 to 72, with higher scores indicating greater disease severity.
The outcome measure is the change in total EASI score from baseline to six-month follow-up.
A negative change indicates improvement.
|
Baseline and six-month follow-up
|
|
Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Six-Month Follow-Up
Prazo: Baseline and six-month follow-up
|
The SCORing Atopic Dermatitis (SCORAD) index includes assessment of disease extent, intensity of skin signs, and subjective symptoms including itching and sleep disturbance.
Total SCORAD scores range from 0 to 103, with higher scores indicating greater disease severity.
The outcome measure is the change in total SCORAD score from baseline to six-month follow-up.
A negative change indicates improvement.
|
Baseline and six-month follow-up
|
|
Number of Participants With Clinically Meaningful Improvement in EASI Score at Week 14
Prazo: Baseline and week 14
|
Clinically meaningful improvement was defined as a reduction of at least 6.6 points in total EASI score from baseline to week 14.
The outcome measure is the number of participants meeting this responder criterion.
|
Baseline and week 14
|
|
Number of Participants With Clinically Meaningful Improvement in SCORAD Score at Week 14
Prazo: Baseline and week 14
|
Clinically meaningful improvement was defined as a reduction of at least 8.7 points in total SCORAD score from baseline to week 14.
The outcome measure is the number of participants meeting this responder criterion.
|
Baseline and week 14
|
|
Number of Participants With Clinically Meaningful Improvement in EASI Score at Six-Month Follow-Up
Prazo: Baseline and six-month follow-up
|
Clinically meaningful improvement was defined as a reduction of at least 6.6 points in total EASI score from baseline to six-month follow-up.
The outcome measure is the number of participants meeting this responder criterion.
|
Baseline and six-month follow-up
|
|
Number of Participants With Clinically Meaningful Improvement in SCORAD Score at Six-Month Follow-Up
Prazo: Baseline and six-month follow-up
|
Clinically meaningful improvement was defined as a reduction of at least 8.7 points in total SCORAD score from baseline to six-month follow-up.
The outcome measure is the number of participants meeting this responder criterion.
|
Baseline and six-month follow-up
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Genéticas, Congênitas
- Doenças do sistema imunológico
- Hipersensibilidade, Imediata
- Hipersensibilidade
- Doenças de pele
- Doenças de Pele Genéticas
- Doenças de Pele, Eczematosas
- Dermatite
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças da Pele e do Tecido Conjuntivo
- Dermatite Atópica
Outros números de identificação do estudo
- ORG-100023482
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
Prazo de Compartilhamento de IPD
Critérios de acesso de compartilhamento IPD
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .